Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: A nationwide population-based study - 02/04/21
, Hai-Jun Wang a, 1, ⁎ Highlights |
• | Prevalence of HPV infection was 15.0% in the pre-vaccine era in China. |
• | Vaccine-targeted HPV-52, -58, and -16 were most common in general population. |
• | HPV prevalence significantly differed across age groups and geographic locations. |
• | HPV prevalence is high and HPV vaccination strategy is needed in China. |
Summary |
Objective |
The HPV vaccine has been licensed in mainland China since 2017. This study aimed to assess the epidemiological characteristics of HPV genotypes in the pre-vaccine era in China.
Methods |
We conducted a multicentric population-based study nested in the largest health clinic chain in China. Between January 1, 2017 and December 31, 2017, 427,401women aged 20 years or older with polymerase chain reaction-based HPV genotyping tests were included in the study. The cervicovaginal infection of 14 high-risk HPV genotypes and 9 low-risk genotypes was assessed using adjusted prevalence, multivariable logistic regression, cluster analysis, and heatmap.
Results |
HPV prevalence was 15.0% (95% confidence interval [CI]: 14.1–15.9%) in China, with high- and low-risk genotypes being 12.1% (95%CI: 11.4–12.7%) and 5.2% (95%CI: 4.8–5.7%), respectively. The prevalence of HPV genotypes corresponding to bivalent, quadrivalent, and nonavalent vaccines were 2.1%, 2.4%, and 8.3%, respectively, whereas the prevalence of non-vaccine high-risk genotypes was 5.7%. The most common high-risk genotypes were HPV-52 (3.5%), HPV-58 (2.1%), and HPV-16 (1.6%), and the prevalence of HPV-18 (0.6%), HPV-6 (0.1%), and HPV-11 (0.2%) were relatively low. Infection with HPV genotypes differed significantly across age groups and geographic locations.
Conclusion |
HPV prevalence was high in the pre-vaccine era in China, and a population-based HPV vaccination strategy is needed in the future.
Le texte complet de cet article est disponible en PDF.Keywords : Human papillomavirus, Prevalence, Genotype, Vaccine
Plan
Vol 82 - N° 4
P. 75-83 - avril 2021 Retour au numéro
Article précédent
- SARS-CoV-2 infections in children following the full re-opening of schools and the impact of national lockdown: Prospective, national observational cohort surveillance, July-December 2020, England
- Anna A Mensah, Mary Sinnathamby, Asad Zaidi, Laura Coughlan, Ruth Simmons, Sharif A Ismail, Mary E Ramsay, Vanessa Saliba, Shamez N Ladhani
- Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department
- Wolfgang Bauer, Eva Diehl-Wiesenecker, Jannis Ulke, Noa Galtung, Aleksandra Havelka, J. Kolja Hegel, Rudolf Tauber, Rajan Somasundaram, Kai Kappert
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?